Showing results (251-260 of 760) with videos related to

Sort By:
Pageof 76
Blood|May 16, 2002
Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applicationsNicholas Mitsiades, Constantine S Mitsiades, Vassiliki Poulaki, et al.
British Journal of Haematology|July 13, 2010
Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myelomaPaul G Richardson, Ashraf Z Badros, Sundar Jagannath, et al.
The Journal of Pharmacy and Pharmacology|August 21, 2010
JS-K has potent anti-angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivoTanyel Kiziltepe, Kenneth C Anderson, Jeffery L Kutok, et al.
Blood|June 26, 2004
Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cellsDharminder Chauhan, Guilan Li, Klaus Podar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 27, 2017
Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple MyelomaMorihiko Sagawa, Hiroto Ohguchi, Takeshi Harada, et al.
Oncoimmunology|August 18, 2025
CyTOF profiling of bone marrow immune dynamics across myeloma stagesDana Cholujova, Gabor Beke, Lubos Klucar, et al.
Blood|July 16, 2016
Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implicationGang An, Chirag Acharya, Xiaoyan Feng, et al.
Experimental Hematology|June 26, 2007
Alkyl phospholipid perifosine induces myeloid hyperplasia in a murine myeloma modelLaurence Catley, Teru Hideshima, Dharminder Chauhan, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|January 7, 2009
Insulin-like growth factor-1- and interleukin-6-related gene variation and risk of multiple myelomaBrenda M Birmann, Rulla M Tamimi, Edward Giovannucci, et al.
Nature Methods|April 23, 2005
Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomibCelia R Berkers, Martijn Verdoes, Eben Lichtman, et al.
Pageof 76